e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Asthma treatment: novel insights from clinical studies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma
H. Ortega (San Diego, United States of America), M. Fitzgerald (Boston, United States of America), K. Raghupathi (San Diego, United States of America), C. Tompinks (San Diego, United States of America), D. Singh (Manchester, United Kingdom)
Source:
International Congress 2019 – Asthma treatment: novel insights from clinical studies
Session:
Asthma treatment: novel insights from clinical studies
Session type:
Poster Discussion
Number:
3713
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Ortega (San Diego, United States of America), M. Fitzgerald (Boston, United States of America), K. Raghupathi (San Diego, United States of America), C. Tompinks (San Diego, United States of America), D. Singh (Manchester, United Kingdom). Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma. 3713
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011
Heterogeneous response of airway eosinophilia to biologics in severe asthma patients
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
Role of neutrophils in airway inflammation in children with severe persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 142s
Year: 2002
Airway inflammation in non-eosinophilic atopic asthma: comparisons with eosinophilic atopic asthma and COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 733s
Year: 2005
Association between eosinophilic airway inflammation and T-cells response in children with bronchial asthma
Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung
Year: 2010
IL-33 in patients with severe uncontrolled allergic asthma
Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Year: 2017
Airways inflammation is related to bronchial responsiveness only in atopic subjects with rhinitis and/or asthma
Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis
Year: 2008
The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia
Source: Eur Respir J 2014; 44: 239-241
Year: 2014
Markers of severity and inflammatory profile during exacerbations of severe asthma.
Source: International Congress 2017 – Airway disease and exacerbations
Year: 2017
Mast cells are associated with exacerbations and eosinophilia in children with severe asthma
Source: Eur Respir J 2016; 48: 1320-1328
Year: 2016
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Allergic inflammation markers for earlier diagnosis of bronchial asthma in patients with allergic rhinitis
Source: Annual Congress 2008 - Asthma: growing understanding of influential factors
Year: 2008
Effects of formoterol-budesonide combination on residual eosinophilic inflammation in distal airway of patients with well-controlled moderate asthma
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Estrogen prevents airway inflammation and hyperresponsiveness in a murine model of acute allergic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 360s
Year: 2007
Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma
Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma
Year: 2019
Relationship between bronchial hyperresponsiveness and response to β
2
-agonists in steroid-naïve patients with mild asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 503s
Year: 2002
Effect of an inhaled alpha4-antagonist on the allergen-induced late asthmatic response in patients with mild asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 135s
Year: 2005
Peanut sensitisation is independently associated with increased airways inflammation in allergic asthma
Source: Annual Congress 2011 - Biomarkers of allergic inflammation
Year: 2011
Airway remodelling is present in children with asthma regardless of eosinophilic inflammation
Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma
Year: 2009
Surrogate markers of airway inflammation are not increased in actively smoking mild to moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 283s
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept